MA31884B1 - Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 - Google Patents
Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3Info
- Publication number
- MA31884B1 MA31884B1 MA32778A MA32778A MA31884B1 MA 31884 B1 MA31884 B1 MA 31884B1 MA 32778 A MA32778 A MA 32778A MA 32778 A MA32778 A MA 32778A MA 31884 B1 MA31884 B1 MA 31884B1
- Authority
- MA
- Morocco
- Prior art keywords
- kiase
- thienopyrimidine
- inhibitors
- mtor kinase
- pyrazolopyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des composés thiénopyrimidine et pyrazolopyrimidine répondant aux formules (ia) et (iia), ou un sel pharmaceutiquement acceptable de ceux-ci, les variables des constituants étant telles que définies dans les présentes compositions comprenant les composés, ainsi que des procédés de fabrication et d'utilisation des composés.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98033207P | 2007-10-16 | 2007-10-16 | |
US2759508P | 2008-02-11 | 2008-02-11 | |
PCT/US2008/079940 WO2009052145A1 (fr) | 2007-10-16 | 2008-10-15 | Composés thiénopyrimidine et pyrazolopyrimidine et leur utilisation en tant que des inhibiteurs de la kinase mtor et de la kinase pi3 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31884B1 true MA31884B1 (fr) | 2010-12-01 |
Family
ID=40345078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32778A MA31884B1 (fr) | 2007-10-16 | 2010-04-16 | Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 |
Country Status (26)
Country | Link |
---|---|
US (1) | US8129371B2 (fr) |
EP (1) | EP2212333A1 (fr) |
JP (1) | JP2011500702A (fr) |
KR (1) | KR20100083170A (fr) |
CN (1) | CN101883774A (fr) |
AP (1) | AP2010005234A0 (fr) |
AR (1) | AR068898A1 (fr) |
AU (1) | AU2008312631A1 (fr) |
BR (1) | BRPI0817681A2 (fr) |
CA (1) | CA2702838A1 (fr) |
CL (1) | CL2008003061A1 (fr) |
CO (1) | CO6321257A2 (fr) |
CR (1) | CR11373A (fr) |
DO (1) | DOP2010000118A (fr) |
EA (1) | EA201000484A1 (fr) |
EC (1) | ECSP10010112A (fr) |
IL (1) | IL205109A0 (fr) |
MA (1) | MA31884B1 (fr) |
MX (1) | MX2010004260A (fr) |
NI (1) | NI201000060A (fr) |
PA (1) | PA8799101A1 (fr) |
PE (1) | PE20091384A1 (fr) |
TN (1) | TN2010000171A1 (fr) |
TW (1) | TW200922593A (fr) |
WO (1) | WO2009052145A1 (fr) |
ZA (1) | ZA201003430B (fr) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1953417B (zh) * | 1996-09-04 | 2010-12-29 | 英特托拉斯技术公司 | 一种从用户站点向外部站点发布使用数据的方法 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
DK2298815T3 (en) | 2005-07-25 | 2015-06-15 | Emergent Product Dev Seattle | B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES |
SG172698A1 (en) | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
EP2231661A1 (fr) | 2007-12-19 | 2010-09-29 | Amgen, Inc. | Inhibiteurs de la pi3 kinase |
ES2368700T3 (es) | 2008-04-11 | 2011-11-21 | Emergent Product Development Seattle, Llc | Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo. |
TW201004963A (en) * | 2008-07-03 | 2010-02-01 | Targacept Inc | Derivatives of oxabispidine as neuronal nicotinic acetylcholine receptor ligands |
WO2010014939A1 (fr) * | 2008-07-31 | 2010-02-04 | Genentech, Inc. | Composés de pyrimidine, compositions et procédés d'utilisation |
ES2464461T3 (es) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
PL3372605T3 (pl) | 2008-10-22 | 2022-03-07 | Array Biopharma Inc. | Podstawione związki pirazolo[1,5-a]pirymidynowe jako inhibitory kinaz trk |
MX2011007326A (es) * | 2009-01-08 | 2011-10-19 | Curis Inc | Inhibidores de fosfoinositida 3-quinasa con una porcion de enlace de cinc. |
ES2439793T3 (es) * | 2009-04-17 | 2014-01-24 | Wyeth Llc | Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis |
AU2010254161A1 (en) * | 2009-05-27 | 2011-11-10 | F. Hoffmann-La Roche Ag | Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use |
EP2445346A4 (fr) * | 2009-06-24 | 2012-12-05 | Genentech Inc | Composés pyrimidine fusionnés à oxo-hétérocycles, compositions et procédés d'utilisation |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
US20110021515A1 (en) * | 2009-07-24 | 2011-01-27 | Takeda Pharmaceutical Company Limited | Dihyrofuropyrmindine compounds |
KR101147550B1 (ko) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물 |
EP2498780B1 (fr) * | 2009-11-12 | 2016-09-07 | F.Hoffmann-La Roche Ag | Composés de purine n-9-substitués, compositions et procédés d'utilisation |
RU2515541C2 (ru) | 2009-11-12 | 2014-05-10 | Ф.Хоффманн-Ля Рош Аг | N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения |
WO2011078795A1 (fr) * | 2009-12-21 | 2011-06-30 | S*Bio Pte Ltd | Purines pontées à substitution morpholino |
EP2525659B1 (fr) * | 2010-01-19 | 2019-02-27 | Merck Sharp & Dohme Corp. | COMPOSÉS PYRAZOLO[1,5-a]PYRIMIDINES EN TANT QU'INHIBITEURS DE mTOR |
UA110697C2 (uk) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
EP2556374A1 (fr) | 2010-04-05 | 2013-02-13 | Wyeth LLC | Biomarqueurs d'un cancer favorisé par la pi3k |
SG10201506591TA (en) | 2010-05-20 | 2015-09-29 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
US9376664B2 (en) | 2010-06-14 | 2016-06-28 | The Scripps Research Institute | Reprogramming of cells to a new fate |
CA2818889A1 (fr) * | 2010-11-24 | 2012-05-31 | Exelixis, Inc. | Benzoxazepines en tant qu'inhibiteurs de pi3k/mtor et procedes de leurs utilisation et fabrication |
WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
WO2012099581A1 (fr) | 2011-01-19 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Composés de dihydrofuropyrimidine |
WO2013019927A1 (fr) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification d'un profil d'expression génique à titre de biomarqueur prédictif de l'état lkb1 |
FR2985257B1 (fr) * | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
EP2809673B1 (fr) * | 2012-01-31 | 2016-11-02 | Nanjing Allgen Pharma Co. Ltd. | Molécules spirocycliques en tant qu'inhibiteurs de tyrosine kinase de bruton |
JP6077642B2 (ja) * | 2012-04-10 | 2017-02-08 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用 |
CN103374021B (zh) * | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
KR20160027218A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
CA2876689C (fr) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Composes tricycliques substitues utilises comme inhibiteurs de fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
TWI631949B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用tor激酶抑制劑組合療法以治療癌症之方法 |
WO2014172423A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Formulations pharmaceutiques, procédés, formes solides et méthodes d'utilisation associés à la 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
EP4218763A1 (fr) | 2013-04-17 | 2023-08-02 | Signal Pharmaceuticals, LLC | 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one pour le traitement du glioblastome multiforme |
MX368286B (es) | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
CA2908957C (fr) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Polytherapie comportant un compose dihydropyrazino-pyrazine et un antagoniste d'un recepteur des androgenes pour le traitement du cancer de la prostate |
EP2986319A1 (fr) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Thérapie combinée comprenant un inhibiteur de la kinase tor et du n-(3-(5-fluoro-2-(4-(2-méthoxyéthoxy)phénylamino)pyrimidin-4-ylamino)phényl)acrylamide pour le traitement d'un cancer |
WO2014172426A1 (fr) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Traitement du cancer par des dihydropyrazino-pyrazines |
HUE036571T2 (hu) | 2013-04-19 | 2018-07-30 | Incyte Holdings Corp | Biciklusos heterociklusok mint FGFR inhibitorok |
CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
CN104513254B (zh) * | 2013-09-30 | 2019-07-26 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用 |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
EP3131551A4 (fr) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | Formes solides comprenant 1-éthyl-7-(2-méthyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1h)-one, et co-formateur, compositions et procédés d'utilisation de ces dernières |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
MX2016014878A (es) | 2014-05-14 | 2017-03-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas. |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
FI3699181T3 (fi) | 2014-11-16 | 2023-03-28 | Array Biopharma Inc | Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP3259269B9 (fr) | 2015-02-20 | 2020-03-04 | Incyte Corporation | Heterocycles bicycliques en tant qu'inhibiteurs de fgfr |
CA2999138C (fr) | 2015-09-21 | 2024-05-21 | Aptevo Research And Development Llc | Polypeptides de liaison a cd3 |
TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
FR3046792B1 (fr) * | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
MA44610A (fr) | 2016-04-04 | 2019-02-13 | Loxo Oncology Inc | Formulations liquides de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
PT3800189T (pt) | 2016-05-18 | 2023-07-27 | Array Biopharma Inc | Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
CN108358949A (zh) * | 2018-03-01 | 2018-08-03 | 南京法恩化学有限公司 | 一种2,4-二氯噻吩并[3,2-d]嘧啶的制备方法 |
CR20200590A (es) | 2018-05-04 | 2021-04-26 | Incyte Corp | Formas sólidas de un inhibidor de fgfr y procesos para prepararlas |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
CN110850012B (zh) * | 2018-08-21 | 2022-07-08 | 四川弘远药业有限公司 | 一种1-(2,3-二氯苯基)哌嗪盐酸盐及其有关物质的检测方法 |
CA3127686A1 (fr) * | 2019-02-06 | 2020-08-13 | Venthera, Inc. | Inhibiteurs de phosphoinositide 3-kinase topiques |
CN111646995B (zh) * | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
CN109824701B (zh) * | 2019-03-26 | 2021-08-13 | 武汉工程大学 | 一种吡啶并噻唑类化合物及其制备方法和应用 |
WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
EP3800188A1 (fr) | 2019-10-02 | 2021-04-07 | Bayer AG | Pyrazolopyrimidines substituées en tant qu'inhibiteurs d'irak4 |
KR20220100879A (ko) | 2019-10-14 | 2022-07-18 | 인사이트 코포레이션 | Fgfr 저해제로서의 이환식 헤테로사이클 |
WO2021076728A1 (fr) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
WO2021113479A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
CA3162010A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derives d'un inhibiteur de fgfr |
WO2021146424A1 (fr) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
CN113278015B (zh) * | 2021-05-31 | 2022-05-13 | 云南大学 | 一种荧光探针及其制备方法和应用 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
-
2008
- 2008-10-15 US US12/251,712 patent/US8129371B2/en not_active Expired - Fee Related
- 2008-10-15 CN CN2008801190434A patent/CN101883774A/zh active Pending
- 2008-10-15 AU AU2008312631A patent/AU2008312631A1/en not_active Abandoned
- 2008-10-15 CA CA2702838A patent/CA2702838A1/fr not_active Abandoned
- 2008-10-15 JP JP2010530074A patent/JP2011500702A/ja not_active Withdrawn
- 2008-10-15 EA EA201000484A patent/EA201000484A1/ru unknown
- 2008-10-15 MX MX2010004260A patent/MX2010004260A/es not_active Application Discontinuation
- 2008-10-15 AP AP2010005234A patent/AP2010005234A0/xx unknown
- 2008-10-15 BR BRPI0817681 patent/BRPI0817681A2/pt not_active Application Discontinuation
- 2008-10-15 WO PCT/US2008/079940 patent/WO2009052145A1/fr active Application Filing
- 2008-10-15 EP EP08839537A patent/EP2212333A1/fr not_active Withdrawn
- 2008-10-15 KR KR1020107010683A patent/KR20100083170A/ko not_active Application Discontinuation
- 2008-10-16 TW TW097139718A patent/TW200922593A/zh unknown
- 2008-10-16 PA PA20088799101A patent/PA8799101A1/es unknown
- 2008-10-16 PE PE2008001780A patent/PE20091384A1/es not_active Application Discontinuation
- 2008-10-16 CL CL2008003061A patent/CL2008003061A1/es unknown
- 2008-10-16 AR ARP080104520A patent/AR068898A1/es unknown
-
2010
- 2010-04-15 NI NI201000060A patent/NI201000060A/es unknown
- 2010-04-15 IL IL205109A patent/IL205109A0/en unknown
- 2010-04-15 CR CR11373A patent/CR11373A/es not_active Application Discontinuation
- 2010-04-16 DO DO2010000118A patent/DOP2010000118A/es unknown
- 2010-04-16 MA MA32778A patent/MA31884B1/fr unknown
- 2010-04-16 EC EC2010010112A patent/ECSP10010112A/es unknown
- 2010-04-16 TN TN2010000171A patent/TN2010000171A1/fr unknown
- 2010-04-20 CO CO10046199A patent/CO6321257A2/es not_active Application Discontinuation
- 2010-05-14 ZA ZA2010/03430A patent/ZA201003430B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201003430B (en) | 2011-02-23 |
CO6321257A2 (es) | 2011-09-20 |
CL2008003061A1 (es) | 2009-01-09 |
AR068898A1 (es) | 2009-12-16 |
EA201000484A1 (ru) | 2010-12-30 |
EP2212333A1 (fr) | 2010-08-04 |
TW200922593A (en) | 2009-06-01 |
CA2702838A1 (fr) | 2009-04-23 |
AP2010005234A0 (en) | 2010-04-30 |
TN2010000171A1 (fr) | 2011-11-11 |
PA8799101A1 (es) | 2009-05-15 |
DOP2010000118A (es) | 2010-06-30 |
ECSP10010112A (es) | 2010-08-31 |
AU2008312631A1 (en) | 2009-04-23 |
WO2009052145A1 (fr) | 2009-04-23 |
NI201000060A (es) | 2010-10-04 |
CN101883774A (zh) | 2010-11-10 |
CR11373A (es) | 2010-05-03 |
US20090098086A1 (en) | 2009-04-16 |
IL205109A0 (en) | 2010-11-30 |
MX2010004260A (es) | 2010-04-30 |
KR20100083170A (ko) | 2010-07-21 |
JP2011500702A (ja) | 2011-01-06 |
PE20091384A1 (es) | 2009-09-09 |
US8129371B2 (en) | 2012-03-06 |
BRPI0817681A2 (pt) | 2015-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31884B1 (fr) | Dérivés de thiénopyrimidine et pyrazolopyrimidine et leur utilisation comme inhibiteurs de la kinase mtor et de la kinase ki3 | |
MA32615B1 (fr) | Inhibiteurs de cmet | |
WO2007120980A3 (fr) | Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes | |
ATE479687T1 (de) | Kinaseinhibitoren | |
WO2006105127A8 (fr) | Inhibiteurs de l'hydroxysteroide deshydrogenase | |
WO2006066109A3 (fr) | Inhibiteurs des hydroxysteroides deshydrogenases | |
MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
WO2006123113A3 (fr) | Composes chimiques | |
MY146989A (en) | Kinase inhibitors | |
WO2008007211A8 (fr) | Composés de carboxyamide bicycliques à n-bicycloalkyle substitué | |
TW200612958A (en) | Substituted imidazole derivatives | |
EA200700225A1 (ru) | Аналоги тетрапептида | |
WO2007028135A3 (fr) | Composes a base d'imidazopyridine | |
WO2007129195A3 (fr) | 4-pyrimidine-5-amino-pyrazoles | |
TW200621753A (en) | Pyrimidinylimidazoles and methods of making and using the same | |
WO2006028963A3 (fr) | Composes heterocycliques substitues et leurs utilisations | |
WO2006125555A3 (fr) | Chinazolinones | |
DE602006020295D1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel | |
ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
TW200621752A (en) | Pyrimidinylpyrazoles and methods of making and using the same | |
WO2008086122A3 (fr) | Dérivés cyclisés en tant qu'inhibiteurs d'eg-5 | |
DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
MA31834B1 (fr) | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires | |
WO2005097087A3 (fr) | Composes combines de modulation du canal ionique et utilisation desdits composes | |
MA32343B1 (fr) | Pyrimidyle cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt |